fda compounding semaglutide crackdown news today 2025 Report: must enforce rules on compounded GLP-1s FDA proposes a new GLP-1

More focus should be put on this aspect since it is due to the rapid weight loss with glp-1s

Is there a reason why they've not offered you a loading dose of every other day for 2 weeks/ or until further improvement if you've neurological problems

Engineered for Severe Obesity and Complex Metabolic Disorders Retatrutides triple-agonist model is intended to help individuals with strong metabolic resistance, such as those who: plateau on semaglutide struggle with long-term weight maintenance experience rapid metabolic slowdown during dieting have severe insulin resistance or fatty liver issues Potential Beyond Weight Management Ongoing studies are exploring retatrutides ability to improve: insulin sensitivity liver-fat clearance cardiovascular risk markers inflammatory markers stabilization of long-term metabolic function These features suggest retatrutide may evolve into a broader therapeutic option than current GLP-1 drugs

Its power lies in its ability to tackle inflammation, repair damaged tissue, and correct cellular dysfunction simultaneously

The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: A systematic review of anti-inflammatory and metabolic effects